Billy Kelleher
Question:558. Deputy Billy Kelleher asked the Minister for Health his views that the new medicines pricing agreement will act as a biosimilars blocker, due to a clause which states that biologics will only be reimbursed at a price 30% less than the current level, and only when competitor biosimilar medicines enter the market; his further views that this cannot occur, as biosimilars will financially be prevented from entering the market, as it would be unsustainable to lower their price further; and if he will make a statement on the matter. [21014/16]
View answer